Programmed death ligand 1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features.
Programmed death ligand 1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features.
复制标题
DOI：
--
复制
发表时间：
2017
影响因子：
1.4
通讯作者：
P. Zhou;Qiongren Wang;Chongshan Wang;Xiezhao Li;W. Du;Chunxiao Liu;Masami Watanabe;Peng Huang;A. Xu
中科院分区：
文献类型：
--
作者：
P. Zhou;Qiongren Wang;Chongshan Wang;Xiezhao Li;W. Du;Chunxiao Liu;Masami Watanabe;Peng Huang;A. Xu
本研究的目的是检测PD-L1在膀胱横纹肌肉瘤中的表达及其与临床病理特征和患者预后的关系。采用免疫组织化学方法检测34例膀胱横纹肌肉瘤石蜡包埋切片中PD-L1的表达。对免疫组化结果进行统计学分析，以确定其与患者临床病理特征和生存结局的相关性。在47.1%（16/34）的患者中观察到PD-L1阳性染色。2例患者淋巴结中的转移性肿瘤细胞PD-L1表达阳性。PD-L1表达在肌层浸润方面有显著差异，但表达不影响患者的生存结局。我们证实了PD-L1在膀胱横纹肌肉瘤中的表达，表明PD-1/PD-L1抑制剂是膀胱横纹肌肉瘤患者的潜在治疗药物。
The aim of this study was to detect PD-L1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features and patient prognosis. PD-L1 expression was detected in paraffin-embedded sections obtained from 34 patients with bladder rhabdomyosarcoma via immunohistochemistry. Immunohistochemistry results were statistically analyzed to determine their association with patient clinicopathological features and survival outcomes. PD-L1-positive staining was observed in 47.1% (16/34) of patients. Metastatic tumor cells in the lymph nodes of two patients were positive for PD-L1 expression. PD-L1 expression was significantly different with regard to muscularis invasion, but the expression did not affect patient survival outcomes. We confirmed PD-L1 expression in bladder rhabdomyosarcoma, suggesting that PD-1/PD-L1 inhibitors are potential therapeutic agents for patients with bladder rhabdomyosarcoma.